Table 1.
Characteristics of study collective
| Characteristics | Overall | cTACE | DEB-TACE | P-value |
|---|---|---|---|---|
| Patients, n (%) | ||||
| Total | 32 (100) | 18 (56.3) | 14 (43.8) | 0.854 |
| Male | 30 (93.8) | 17 (94.4) | 13 (92.9) | |
| Female | 2 (6.3) | 1 (5.6) | 1 (7.1) | |
| Age (years) | ||||
| Mean | 66.8 | 68.5 | 64.7 | 0.2613 |
| Tumor burden, n (%) | ||||
| Unilobar | 12 (37.5) | 7 (38.8) | 5 (35.7) | 0.854 |
| Bilobar | 20 (62.5) | 11 (61.1) | 9 (64.3) | |
| Multinodular (≥4 nodes) | 19 (59.4) | 8 (44.4) | 11 (78.6) | 0.0512 |
| Okuda stage,a n (%) | ||||
| I | 12 (40.0) | 7 (43.8) | 5 (35.7) | 0.7398 |
| II | 15 (50.0) | 7 (43.8) | 8 (57.1) | |
| III | 3 (10.0) | 2 (12.5) | 1 (7.1) | |
| Child-Pugh class,a n (%) | ||||
| A | 21 (67.7) | 10 (58.8) | 11 (78.6) | 0.3200 |
| B | 8 (25.8) | 5 (29.7) | 3 (21.4) | |
| C | 2 (6.5) | 2 (11.8) | 0 (0.0) | |
| MELD scorea | ||||
| Mean | 10.0 | 11.1 | 8.8 | 0.0771 |
| Targeted therapy, n (%) | ||||
| Sorafenib after initial TACE | 14 (41.4) | 6 (33.3) | 8 (57.1) | 0.1780 |
Note:
a
In up to two cases, patients could not be classified due to missing data.
Abbreviations: cTACE, conventional transarterial chemoembolization; DEB-TACE, transarterial chemoembolization with drug-eluting beads; MELD, Model for End-stage Liver Disease; TACE, transarterial chemoembolization.